![]() ![]() Now Datavant will take that one more big step forward, gathering massive quantities of drug data and using artificial information tech to find more drugs for the pipeline. Its lead drug is Axovant’s Alzheimer’s med, bagged from GSK and now about to spell out Phase III data. Browse plot descriptions, book covers, genres, pseudonyms, ratings and awards. Ramaswamy has created a multifaceted biotech company with a slate of startups that have been gathering assets from the bargain basements of the world’s biggest pharma companies. A complete list of all Glynne MacLeans books & series in order (1 books) (1 series). The young Travis May, recognized last year in one of Forbes’ 30 under 30 lists, is taking the helm at the fledgling Datavant, Vivek Ramaswamy’s new operation designed to build on its work in gathering data on a pipeline of shelved therapies. Roivant Sciences, an unusual holding company with roughly a dozen biotech subsidiaries, will go public through a merger with a blank-check entity in a deal that values the company at 7.3 billion. And today, he’s not only taking the lead on Roivant Sciences’ ambitious new effort to translate mass data into better drugs that can be efficiently developed, he’s investing in the company as well. ![]() ![]() As a founder of LiveRamp, Travis May was lionized for his role in building one of the most technologically sophisticated data onboarding outfits, which specialized in reaching a mass consumer audience. ![]()
0 Comments
Leave a Reply. |